Engineered microbe-based micro/nanorobots redefine interventional therapy for luminal cancers
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Oct-2026 05:16 ET (25-Oct-2026 09:16 GMT/UTC)
A new review in Medicine Plus outlines a transformative paradigm for luminal cancers using engineered microbe-based micro/nanorobots. Deployed via oral, suppository, or intracavitary routes, these living platforms bypass physiological barriers, colonize tumor niches, continuously synthesize therapeutics, and remodel the tumor microenvironment. Merging microbial adaptability with synthetic biology, they usher in an era of persistent, spatially controlled intervention.
A new review in Medicine Plus traces the evolution of mRNA lipid nanoparticles (mRNA-LNPs) from prophylactic vaccine vehicles to programmable therapeutic platforms. The authors detail clinical and preclinical progress across infectious disease, cancer, autoimmunity, rare genetic disease and tissue repair, while identifying key translational hurdles including extrahepatic targeting, repeat-dose immunogenicity, off-target editing risks, and scalable manufacturing.
Generative AI is increasingly being explored across cancer care, yet the patients, survivors and carers that AI intends to support have had little opportunity to shape how these tools are developed, evaluated and used - a Flinders University-led review has found.
The use of Artificial Intelligence (AI) tools to take notes can change the nature of interactions between patients and clinicians, sometimes missing vital information, according to the results of a new review. The report also states that use of these tools, referred to as ambient AI scribes, may lead to deskilling and deprive clinicians of opportunities to acquire clinical reasoning skills. While ambient AI scribes can help with administrative work, more research needs to be done to understand how these tools work in specific healthcare settings and how their design supports both patients and clinicians, experts say.